Skip to content

Medical emergency? What to do

Lilly gets FDA nod on new osteoporosis drug use

3-RXPublished September 16, 20073 min read

Key points

  • Eli Lilly & Co said Friday that it had won approval to market its blockbuster osteoporosis drug to post-menopausal women who are at high risk for invasive breast cancer.
  • However, the drug will also contain a stronger warning of side effects that can include death by stroke.
  • Lilly said Evista, like the hormone estrogen, helps to fight osteoporosis.
  • SERMs are drugs used to treat osteoporosis that also appear to prevent breast cancer by reducing estrogen in breast tissue.

Eli Lilly & Co said Friday that it had won approval to market its blockbuster osteoporosis drug to post-menopausal women who are at high risk for invasive breast cancer.

The company also said U.S. health regulators had extended the use of the drug, known as Evista, to help reduce the risk of the aggressive form of breast cancer in post-menopausal women who have the bone-thinning disease.

However, the drug will also contain a stronger warning of side effects that can include death by stroke.

Evista, known generically as raloxifene, is already approved for the prevention and treatment of osteoporosis, or bone thinning, in post-menopausal women.

Lilly said Evista, like the hormone estrogen, helps to fight osteoporosis. But Evista also blocks estrogen in breast tissue, the drug maker said.

Sales of Evista, a selective estrogen receptor modulator, topped $1 billion in 2006.

SERMs are drugs used to treat osteoporosis that also appear to prevent breast cancer by reducing estrogen in breast tissue. Estrogen in breast tissue can drive some types of breast cancer.

"This data's been unfolding for the last few years, so it's not as if physicians are not aware of this, but now Lilly will be able to market it," said Deutsche Bank analyst Barbara Ryan.

In 2007, Evista sales were flat with the prior year, she noted. "Our view is that this (approval) may begin to deliver some growth of maybe 10 to 20 percent," she said.

That would equate to roughly $100 million to $200 million in incremental revenues annually. "But it doesn't dramatically move the needle at Lilly," Ryan said. "So it's not momentous, but we'll watch the scripts like everyone else, and maybe we'll be surprised."

Lilly, whose other products include antidepressant Prozac and erectile dysfunction drug Cialis, reported second-quarter revenue of $4.63 billion.

Earlier this year, Lilly updated the label for Evista to include safety information from a clinical trial that evaluated post-menopausal women, some of whom were suffering from coronary artery disease and some who were at increased risk for coronary disease.

The trial found no increase in the incidence of stroke but an increase in the incidence of death because of stroke.

Since the new label for Evista will include new uses and an expanded patient population, Lilly has worked with the FDA to revise the package insert. The insert will now emphasize that women with an active or past history of venous thromboembolism - potentially deadly blood clots - should not take Evista and that women at risk for stroke should receive the drug only after careful evaluation.

A company spokeswoman said the so-called black-box warning did not preclude the company from conducting direct-to-consumer advertising.

The company presented studies of 37,000 women that compared Evista with a placebo or tamoxifen, which has been used about 25 years to treat patients with advanced breast cancer.

Competing osteoporosis drugs include Merck & Co Inc's Fosamax, and Roche Holding AG'sand GlaxoSmithKline Plc'sBoniva.

Shares of Eli Lilly were down 33 cents at $56.85 in morning New York Stock Exchange trade. Their price has ranged from $51.13 to $60.63 during the past 52 weeks.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug Abuse

Statin label to carry diabetes warning

All statin labels will now include a warning about a small increased risk for elevated blood glucose levels and possible problems with transient memory and cognition, the FDA announced today. The agency will also…

2 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.